A new subcutaneous formulation of furosemide delivered via a wearable pump has been FDA-approved for managing edema in chronic heart failure.
The FDA has approved Lasix ONYU (SQ Innovation), a subcutaneous formulation of the loop diuretic furosemide administered via a wearable pump (on-body infusor), for treatment of edema in adults with chronic heart failure (HF). A similar product, Furoscix, is approved for treatment of edema in chronic HF or chronic kidney disease.1 Furosemide has been available for years in oral and IV formulations for such use.
A Mon, study studied this question.